Advertisement

BioDrugs

, Volume 24, Issue 2, pp 89–98 | Cite as

Bispecific Antibodies for Cancer Immunotherapy

Current Perspectives
  • Dafne Müller
  • Roland E. Kontermann
Review Article

Abstract

The concept of using bispecific antibodies to retarget immune effector cells for cancer therapy was conceived more than 20 years ago. However, initial clinical studies were rather disappointing mainly due to low efficacy, severe adverse effects and immunogenicity of the bispecific antibodies. A deeper understanding of effector cell biology and especially developments in the field of antibody engineering has led to the generation of new classes of bispecific antibodies capable of circumventing many of these obstacles. Furthermore, new applications were established for bispecific antibodies, such as pre-targeting strategies in radioimmunotherapy or dual targeting approaches in order to improve binding, selectivity, and efficacy. This review summarizes recent progress in the development of bispecific antibodies and describes some new concepts developed for cancer immunotherapy.

Keywords

Bispecific Antibody Variable Heavy Hyperthermic Isolate Limb Perfusion Trifunctional Antibody Trigger Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was supported by grants from the Deutsche Forschungsgemeinschaft (KO 1461/4, MU 2956/2-1) and the Deutsche Krebshilfe (MU 2956/2-1). The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Müller D, Kontermann RE. Bispecific antibodies. In: Dübel S, editor. Handbook of therapeutic antibodies. Berlin: Springer, 2007: 345–78CrossRefGoogle Scholar
  2. 2.
    Müller D, Kontermann RE. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007; 9: 319–26PubMedGoogle Scholar
  3. 3.
    Chames P, Baty D. Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Develop 2009; 12: 276–83Google Scholar
  4. 4.
    Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98: 2526–34PubMedCrossRefGoogle Scholar
  5. 5.
    Kontermann RE. Alternative antibody formats. Curr Opin Mol Ther. In pressGoogle Scholar
  6. 6.
    Wu C, Ying H, Grinnell C, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25: 1290–7PubMedCrossRefGoogle Scholar
  7. 7.
    Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009; 11: 22–30PubMedGoogle Scholar
  8. 8.
    Kellner C, Bruenke J, Stieglmaier J, et al. A novel CD 19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 2008; 31: 871–84PubMedCrossRefGoogle Scholar
  9. 9.
    Rossi EA, Sharkey RM, McBride W, et al. Development of new mutlivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 2003; 9: 3886S–96SPubMedGoogle Scholar
  10. 10.
    Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 2005; 26: 1–9PubMedCrossRefGoogle Scholar
  11. 11.
    Saerens D, Ghassabeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 2008; 8: 600–8PubMedCrossRefGoogle Scholar
  12. 12.
    Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009; 13: 245–55PubMedCrossRefGoogle Scholar
  13. 13.
    Friedman M, Lindström S, Ekerljung L, et al. Engineering and characterization of a bispecific HER2xEGFR-binding affibody molecule. Biotechnol Appl Biochem 2009; 54: 121–31PubMedCrossRefGoogle Scholar
  14. 14.
    Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 2006; 103: 6841–6PubMedCrossRefGoogle Scholar
  15. 15.
    Gold DV, Goldenberg DM, Karacay H, et al. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res 2008; 68: 4819–26PubMedCrossRefGoogle Scholar
  16. 16.
    Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999; 163: 1246–52PubMedGoogle Scholar
  17. 17.
    Sebastian M, Kiewe P, Schuette W, et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) [anti-EpCAM× Anti-CD3]: results of a phase 1/2 study. J Immunother 2009; 32: 195–202PubMedCrossRefGoogle Scholar
  18. 18.
    Ströhlein MA, Siegel R, Jäger M, et al. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis [letter]. J Exp Clin Cancer Res 2009; 28: 18PubMedCrossRefGoogle Scholar
  19. 19.
    Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 2008; 17: 1553–8PubMedCrossRefGoogle Scholar
  20. 20.
    Shen J, Zhu Z. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr Opin Mol Ther 2008; 10: 273–84PubMedGoogle Scholar
  21. 21.
    Kiewe P, Hasmüller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2× anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006; 12: 3085–91PubMedCrossRefGoogle Scholar
  22. 22.
    Gall JM, Davol PA, Grabert RC, et al. T cells armed with anti-CD3 × anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 2005; 33: 452–9PubMedCrossRefGoogle Scholar
  23. 23.
    Dreier T, Baeuerle PA, Fichtner I, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 2003; 170: 4397–402PubMedGoogle Scholar
  24. 24.
    Schlereth B, Quadt C, Dreier T, et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD 19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 2006; 55: 503–14PubMedCrossRefGoogle Scholar
  25. 25.
    Schlereth B, Kleindienst P, Fichtner I, et al. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for murine CD3. Cancer Immunol Immunother 2006; 55: 785–96PubMedCrossRefGoogle Scholar
  26. 26.
    Lutterbuese R, Raum T, Kischel R, et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 2009; 32: 341–52PubMedCrossRefGoogle Scholar
  27. 27.
    Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974–7PubMedCrossRefGoogle Scholar
  28. 28.
    Haas C, Krinner E, Brischwein K, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009; 214: 441–53PubMedCrossRefGoogle Scholar
  29. 29.
    Amann M, D’Argouges S, Lorenczewski G, et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 2009; 32: 452–64PubMedCrossRefGoogle Scholar
  30. 30.
    Amann M, Friedrich M, Lutterbuese P, et al. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. Cancer Immunol Immunother 2009; 58: 95–109PubMedCrossRefGoogle Scholar
  31. 31.
    Bühler P, Wolf P, Gierschner D, et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother 2008; 57: 43–52PubMedCrossRefGoogle Scholar
  32. 32.
    Bühler P, Molnar E, Dopfer EP, et al. Target-dependent T-cell activation by coligation with a PSMA × CD3 diabody induces lysis of prostate cancer cells. J Immunother 2009; 32: 565–73PubMedCrossRefGoogle Scholar
  33. 33.
    Grosse-Hovest L, Hartlapp I, Marwan W, et al. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol 2003; 33(5): 1334–40PubMedCrossRefGoogle Scholar
  34. 34.
    Otz T, Grosse-Hovest L, Hofmann M, et al. A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells. Leukemia 2009; 23(1): 71–7PubMedCrossRefGoogle Scholar
  35. 35.
    Lu D, Zhang H, Ludwig D, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004; 279: 2856–65PubMedCrossRefGoogle Scholar
  36. 36.
    Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280: 19665–72PubMedCrossRefGoogle Scholar
  37. 37.
    Jimenez X, Lu D, Brennan L, et al. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol Cancer Ther 2005; 4: 427–34PubMedGoogle Scholar
  38. 38.
    Robinson MK, Hodge KM, Horak E, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99: 1415–25PubMedCrossRefGoogle Scholar
  39. 39.
    Vallera DA, Chen H, Sicheneder AR, et al. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 2009; 33: 1233–42PubMedCrossRefGoogle Scholar
  40. 40.
    Bostrom J, Yu SF, Kan D, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323: 1610–4PubMedCrossRefGoogle Scholar
  41. 41.
    Goldenberg DM, Chatal JF, Barbet J, et al. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2007; 2: 19–31PubMedCrossRefGoogle Scholar
  42. 42.
    Chatal JF, Campion L, Kraeber-Bodéré F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006; 24: 1705–11PubMedCrossRefGoogle Scholar
  43. 43.
    Balkwill F. Tumor necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361–71PubMedCrossRefGoogle Scholar
  44. 44.
    Grünhagen DJ, de Wilt JH, van Geel AN, et al. Isolated limb perfusion with TNF-alpha and melphalan in locally advaned soft tissue sarcomas of the extremities. Recent Results Cancer Res 2009; 179: 257–70PubMedCrossRefGoogle Scholar
  45. 45.
    Hallahan DE, Vokes EE, Rubin SJ, et al. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. Cancer J Sci Am 1995; 1: 204–9PubMedGoogle Scholar
  46. 46.
    Azria D, Larbouret C, Grambois V, et al. Potentiation of ionising radiation by targeting tumor necrosis factor alpha using a bispecific antibody in human pancreatic cancer. Br J Cancer 2003; 89: 1987–94PubMedCrossRefGoogle Scholar
  47. 47.
    Larbouret C, Robert B, Linard C, et al. Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice. Int J Radiation Oncol Biol Phys 2007; 69: 1231–7CrossRefGoogle Scholar
  48. 48.
    Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. Biodrugs 2009; 23: 93–109PubMedCrossRefGoogle Scholar
  49. 49.
    Stork R, Zettlitz KA, Müller D, et al. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008; 283: 7804–12PubMedCrossRefGoogle Scholar
  50. 50.
    Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002; 54: 531–45PubMedCrossRefGoogle Scholar
  51. 51.
    Stork R, Campigna E, Robert B, et al. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 2009; 284: 25612–9PubMedCrossRefGoogle Scholar
  52. 52.
    Schlapschy M, Theobald I, Mack H, et al. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng Des Sel 2007; 20: 273–84PubMedCrossRefGoogle Scholar
  53. 53.
    Marvin JS, Zhu Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sci 2005; 26: 649–58CrossRefGoogle Scholar
  54. 54.
    Müller D, Karle A, Meissburger B, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007; 282: 12650–60PubMedCrossRefGoogle Scholar
  55. 55.
    Stork R, Müller D, Kontermann RE. A novel trifunctional antibody fusion protein with improved pharmacokientic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain form streptococcal protein G. Protein Eng Des Sel 2007; 20: 569–76PubMedCrossRefGoogle Scholar
  56. 56.
    Tijnk BM, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of molecular nanobody technology. Mol Cancer Ther 2008; 7: 2288–97CrossRefGoogle Scholar
  57. 57.
    Holt LJ, Basran A, Jones K, et al. Anti-serum albumin domain antibodies for extending the half-lvies of short lived drugs. Protein Eng Des Sel 2008; 21: 283–8PubMedCrossRefGoogle Scholar
  58. 58.
    Kufer P, Lutterbüse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol 2004; 22: 238–44PubMedCrossRefGoogle Scholar
  59. 59.
    Melero I, Hervas-Stubbs S, Glennie M, et al. Imunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7: 95–106PubMedCrossRefGoogle Scholar
  60. 60.
    Blanco B, Holliger P, Vile RG, et al. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol 2003; 171: 1070–7PubMedGoogle Scholar
  61. 61.
    Müller D, Frey K, Kontermann RE. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J Immunother 2008; 31: 714–22PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Institut für Zellbiologie und ImmunologieUniversität StuttgartStuttgartGermany

Personalised recommendations